Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Negotiating | 3 | 2024 | 30 | 2.510 |
Why?
|
| Medicare | 4 | 2024 | 719 | 1.900 |
Why?
|
| Cost-Benefit Analysis | 6 | 2025 | 569 | 1.750 |
Why?
|
| Direct-to-Consumer Advertising | 2 | 2024 | 6 | 1.730 |
Why?
|
| Medicare Part D | 3 | 2023 | 26 | 1.670 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 516 | 1.610 |
Why?
|
| Prescription Drugs | 2 | 2023 | 112 | 1.360 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 151 | 0.820 |
Why?
|
| Pregnancy in Diabetics | 1 | 2024 | 118 | 0.810 |
Why?
|
| Medicare Part C | 1 | 2023 | 28 | 0.790 |
Why?
|
| Drug Industry | 1 | 2023 | 106 | 0.740 |
Why?
|
| Public Opinion | 1 | 2022 | 64 | 0.740 |
Why?
|
| Health Equity | 1 | 2023 | 87 | 0.730 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 171 | 0.700 |
Why?
|
| United States | 14 | 2025 | 13913 | 0.650 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2024 | 601 | 0.630 |
Why?
|
| Qualitative Research | 1 | 2024 | 1235 | 0.540 |
Why?
|
| Blood Glucose | 1 | 2024 | 2103 | 0.460 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2024 | 28 | 0.430 |
Why?
|
| Drug Costs | 3 | 2023 | 100 | 0.400 |
Why?
|
| Aged | 8 | 2024 | 22107 | 0.360 |
Why?
|
| Economics, Pharmaceutical | 2 | 2019 | 9 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 3630 | 0.290 |
Why?
|
| Humans | 17 | 2025 | 129847 | 0.270 |
Why?
|
| Genetic Therapy | 2 | 2025 | 293 | 0.250 |
Why?
|
| Costs and Cost Analysis | 2 | 2023 | 201 | 0.250 |
Why?
|
| Cost Savings | 1 | 2024 | 78 | 0.230 |
Why?
|
| Reimbursement Mechanisms | 1 | 2025 | 84 | 0.220 |
Why?
|
| Germany | 1 | 2024 | 100 | 0.220 |
Why?
|
| Medicaid | 2 | 2025 | 433 | 0.210 |
Why?
|
| Medicare Part B | 1 | 2023 | 3 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 106 | 0.210 |
Why?
|
| Hemophilia B | 1 | 2023 | 48 | 0.210 |
Why?
|
| National Health Programs | 1 | 2023 | 17 | 0.210 |
Why?
|
| Psychotherapy | 1 | 2024 | 158 | 0.200 |
Why?
|
| South Africa | 1 | 2023 | 193 | 0.200 |
Why?
|
| Mental Competency | 1 | 2022 | 25 | 0.190 |
Why?
|
| Hemophilia A | 1 | 2023 | 115 | 0.190 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 228 | 0.190 |
Why?
|
| Health Expenditures | 1 | 2023 | 180 | 0.180 |
Why?
|
| Drug Approval | 1 | 2022 | 87 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 253 | 0.180 |
Why?
|
| Informed Consent | 1 | 2022 | 165 | 0.180 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 205 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 5437 | 0.170 |
Why?
|
| Policy | 1 | 2022 | 143 | 0.170 |
Why?
|
| Patient Participation | 1 | 2024 | 414 | 0.170 |
Why?
|
| Economic Competition | 1 | 2019 | 14 | 0.160 |
Why?
|
| Legislation, Drug | 1 | 2019 | 77 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2024 | 14553 | 0.150 |
Why?
|
| Research Design | 1 | 2024 | 1045 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 756 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2024 | 813 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2024 | 5772 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2023 | 5444 | 0.100 |
Why?
|
| Female | 3 | 2024 | 68829 | 0.100 |
Why?
|
| Pregnancy | 1 | 2024 | 6423 | 0.100 |
Why?
|
| Adult | 2 | 2024 | 35634 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 5085 | 0.090 |
Why?
|
| Male | 3 | 2025 | 63759 | 0.080 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2024 | 3 | 0.060 |
Why?
|
| Models, Economic | 1 | 2025 | 53 | 0.060 |
Why?
|
| Markov Chains | 1 | 2025 | 117 | 0.060 |
Why?
|
| Middle Aged | 1 | 2024 | 31177 | 0.050 |
Why?
|
| Japan | 1 | 2019 | 98 | 0.040 |
Why?
|
| Ontario | 1 | 2019 | 90 | 0.040 |
Why?
|
| Public Policy | 1 | 2019 | 70 | 0.040 |
Why?
|
| Colorado | 1 | 2025 | 4410 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2024 | 10241 | 0.020 |
Why?
|